{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:36Z","timestamp":1756902156865,"version":"3.44.0"},"reference-count":10,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"\nOBJECTIVE<\/jats:title>\nThis study aimed to characterize and assess the safety of a 1-hour infliximab infusion in a cohort of pediatric patients.<\/jats:p>\n<\/jats:sec>\n\nMETHODS<\/jats:title>\nA retrospective chart review of pediatric patients that received a 1-hour infliximab or its biosimilar infusion for a gastrointestinal or rheumatologic condition was conducted. Infusions were included if the patient had at least 3 infusions for rheumatology patients and 4 for gastroenterology patients. Patients who were not transitioned to the rapid, 1-hour infusion were excluded. Baseline characteristics, including age, weight, indication, dose, the use of premedications or combination therapy, and the development of anti-infliximab antibodies were analyzed along with any reported safety outcomes related to infusion administration.<\/jats:p>\n<\/jats:sec>\n\nRESULTS<\/jats:title>\nA total of 69 pediatric patients were screened for inclusion, of which 41 patients received 159 infusions. The median age of the population was 15 years, and the sex distribution was nearly equal, with 48.8% of the population representing females. Most patients received infliximab treatment by the pediatric gastroenterology service (87.8%), with Crohn\u2019s disease being the lead indication (75.6%). A small number of patients were managed with combination therapy or premedicated before their infusion. Forty-one patients were routinely monitored for infliximab antibodies, but only 4 developed them (9.8%). Doses ranged from 150 to 1000 mg, depending on patient weight. One patient (0.6%) experienced an adverse reaction during the 1-hour infusion, which resulted in cessation of the infusion, but continued 1-hour infusions at a later date.<\/jats:p>\n<\/jats:sec>\n\nCONCLUSIONS<\/jats:title>\nThis study showcases that 1-hour infliximab infusions are well-tolerated and appear safe in pediatric patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.5863\/1551-6776-30.1.65","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T14:25:22Z","timestamp":1745245522000},"page":"65-69","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Cohort Analysis of 1-Hour Infliximab Infusions in Pediatric Patients"],"prefix":"10.5863","volume":"30","author":[{"given":"Drew","family":"Goodrich","sequence":"first","affiliation":[{"name":"Department of Pharmacy (DG, JS, AG, RK, BC) Tufts Medical Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"George","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (DG, JS, AG, RK, BC) Tufts Medical Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (DG, JS, AG, RK, BC) Tufts Medical Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Koziol","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (DG, JS, AG, RK, BC) Tufts Medical Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brienne","family":"Costigan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (DG, JS, AG, RK, BC) Tufts Medical Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"(4)","key":"i2331-348X-30-1-65-b01","series-title":"Aliment Pharmacol Ther","first-page":"365","article-title":"Meta-analysis: rapid infliximab infusions are safe","volume":"38","author":"Neef","year":"2013","unstructured":"Neef HC, Riebschleger MP, Adler J. Meta-analysis: rapid infliximab infusions are safe. Aliment Pharmacol Ther. 2013;38(4):365\u2013376."},{"issue":"(3)","key":"i2331-348X-30-1-65-b02","series-title":"J Pediatr Gastroenterol Nutr","first-page":"361","article-title":"Safety of rapid infliximab infusions in children: a systematic review","volume":"71","author":"van Wassenaer","year":"2020","unstructured":"van Wassenaer EA, van Oosterhout JPM, Daams JG, et al. Safety of rapid infliximab infusions in children: a systematic review. J Pediatr Gastroenterol Nutr. 2020;71(3):361\u2013365."},{"issue":"(2)","key":"i2331-348X-30-1-65-b03","series-title":"J Pediatr Pharmacol Ther","first-page":"215","article-title":"Rapid infusion of infliximab","volume":"26","author":"Rozette","year":"2021","unstructured":"Rozette NA, Hellauer CM, Dice JE. Rapid infusion of infliximab. J Pediatr Pharmacol Ther. 2021;26(2):215."},{"issue":"(2)","key":"i2331-348X-30-1-65-b04","series-title":"J Pediatr Gastroenterol Nutr","first-page":"e56","article-title":"Rapid infliximab infusions in paediatric inflammatory bowel disease patients, a single hospital experience","volume":"72","author":"Bossacoma Busquets","year":"2021","unstructured":"Bossacoma Busquets F, Pujol Muncunill G, Arrojo Su\u00e1rez J, et al. Rapid infliximab infusions in paediatric inflammatory bowel disease patients, a single hospital experience. J Pediatr Gastroenterol Nutr. 2021;72(2):e56."},{"issue":"(12)","key":"i2331-348X-30-1-65-b05","series-title":"Inflamm Bowel Dis","first-page":"2104","article-title":"Rapid infliximab infusion in children with inflammatory bowel disease: a multicenter North American experience","volume":"23","author":"El-Matary","year":"2017","unstructured":"El-Matary W, Dykes DMH, Bauman L, et al. Rapid infliximab infusion in children with inflammatory bowel disease: a multicenter North American experience. Inflamm Bowel Dis. 2017;23(12):2104\u20132108."},{"issue":"(5)","key":"i2331-348X-30-1-65-b06","series-title":"J Pediatr Gastroenterol Nutr","first-page":"605","article-title":"Rapid infliximab biosimilar infusion in children with inflammatory bowel disease","volume":"74","author":"O\u2019Connell","year":"2022","unstructured":"O\u2019Connell DM, Nachreiner J, Shu X, et al. Rapid infliximab biosimilar infusion in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2022;74(5):605\u2013609."},{"issue":"(5)","key":"i2331-348X-30-1-65-b07","series-title":"J Pediatr Gastroenterol Nutr","first-page":"e101","article-title":"Rapid infliximab infusion in children: a multicenter retrospective cohort study","volume":"65","author":"Lev-Tzion","year":"2017","unstructured":"Lev-Tzion R, Assa A, Yerushalmi B, et al. Rapid infliximab infusion in children: a multicenter retrospective cohort study. J Pediatr Gastroenterol Nutr. 2017;65(5):e101\u2013e103."},{"issue":"(1)","key":"i2331-348X-30-1-65-b08","series-title":"J Pediatr Gastroenterol Nutr","first-page":"151","article-title":"Rapid infliximab infusions in pediatric inflammatory bowel disease","volume":"49","author":"Yeckes","year":"2009","unstructured":"Yeckes AR, Hoffenberg EJ. Rapid infliximab infusions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;49(1):151\u2013154."},{"issue":"(1)","key":"i2331-348X-30-1-65-b09","series-title":"J Paediatr Child Health","first-page":"94","article-title":"Rapid infliximab infusions are generally well-tolerated in children with inflammatory bowel disease","volume":"53","author":"Glover","year":"2017","unstructured":"Glover C, Phuong L, Hinds R. Rapid infliximab infusions are generally well-tolerated in children with inflammatory bowel disease. J Paediatr Child Health. 2017;53(1):94\u201395."},{"issue":"(8)","key":"i2331-348X-30-1-65-b10","series-title":"J Pediatr Pharmacol Ther","first-page":"705","article-title":"Rapid infliximab infusion in the pediatric population","volume":"25","author":"Munsel","year":"2020","unstructured":"Munsel EJ, Bryan PJ, Binstadt BA, et al. Rapid infliximab infusion in the pediatric population. J Pediatr Pharmacol Ther. 2020;25(8):705\u2013708."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/1\/article-p65.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/1\/article-p65.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/1\/article-p65.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T14:25:22Z","timestamp":1745245522000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/1\/article-p65.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":10,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-30.1.65","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}